Prima Biomed Ltd (PBMD) 1.03 $PBMD Prima BioMed to

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 3:18 AM

Prima Biomed Ltd (PBMD) 1.03 $PBMD

Prima BioMed to Maintain NASDAQ Listing
Marketwired - Mon Jun 06, 8:25PM CDT
SYDNEY, AUSTRALIA--(Marketwired - Jun 6, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock Market indicating that the Company's American Depositary Shares have maintained a closing bid price of US$1.00 per share or greater for 10 consecutive business days from 20 May 2016 to 3 June 2016. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule"

and the Company's American Depositary Shares will remain listed on the NASDAQ Global Market.
PBMD: 1.03 (-0.02)

Prima BioMed Enters Into Sale and Licensing Agreement With Sydys to Advance CVac(TM) Program
Marketwired - Thu May 12, 3:26AM CDT
SYDNEY, AUSTRALIA and SEATTLE, WA--(Marketwired - May 12, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 1.03 (-0.02)

Prima BioMed Limited (NASDAQ: PBMD) Analyst Coverage Initiated
ACCESSWIRE - Tue May 03, 7:05AM CDT
SYDNEY, AUSTRALIA / ACCESSWIRE / May 3, 2016 / Prima BioMed Limited (NASDAQ: PBMD) an Australia-based biotechnology company engaged in research, development and commercialization of licensed medical biotechnology, recently announced the granting of patent number 5908210 entitled "Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response" by the Japanese Patent Office. This patent relates to Prima's IMP321 and its use either alone, or in combination, for immunotherapeutic or chemotherapeutic purposes to induce an increase in circulating monocyte numbers in order to protect against cancer. This patent will therefore support the use of IMP321 as it is being used in Prima's AIPAC trial in metastatic breast cancer. Patent expiry is expected to be 3rd of October 2028.
PBMD: 1.03 (-0.02)

Top Stocks on 4/20: Investors Are Considering These on Wednesday April 20th
ACCESSWIRE - Wed Apr 20, 11:57AM CDT
MIAMI, FL / ACCESSWIRE / April 20, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EBIO, ASM, OCLS, and PBMD have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
PBMD: 1.03 (-0.02), EBIO: 1.87 (+0.19), OCLS: 0.96 (unch)

IMP321 Safety and Immune Monitoring Data Published in Clinical Cancer Research Journal
Marketwired - Tue Mar 15, 2:40AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) advises that safety and immune monitoring data from an investigator-led clinical trial in melanoma using IMP321 as an adjuvant to a therapeutic vaccine has been published in the March 15 edition of the Clinical Cancer Research journal. The paper is titled "Vaccination with sLAG-3-Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients: report of a phase I/IIa clinical trial" and is the result of a long-standing academic collaboration between Dr. Frederic Triebel, Prima's Chief Scientific Officer and Chief Medical Officer and scientists at the Ludwig Centre for Cancer Research at the University of Lausanne, Switzerland.
PBMD: 1.03 (-0.02)

Prima Biomed (PBMD) Jumps: Stock Adds 25.6% in Session
Zacks Equity Research - Zacks Investment Research - Fri Mar 11, 7:15AM CST
Prima Biomed Ltd. (PBMD) shares rose almost 26% in the last trading session.
PBMD: 1.03 (-0.02), ANIK: 49.16 (+0.24)

Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency
Marketwired - Fri Mar 04, 12:35AM CST
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima," the "Company"

, has received notification from the Listing Qualifications Department of The NASDAQ Stock Market (the "Staff"

indicating that, for the period from January 13, 2016 through February 26, 2016, the closing bid price of the Company's American Depositary Shares, or ADS, had not been maintained at the minimum required closing bid price of at least US$1.00 per share as required for continued listing on The NASDAQ Global Market pursuant to NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule"

.
PBMD: 1.03 (-0.02)

Prima BioMed wins US patent for IMP731 Antibody
M2 - Thu Jan 28, 3:34AM CST
Biotechnology company Prima BioMed (ASX

RR) (NASDAQ

BMD) disclosed on Wednesday the receipt of the patent entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" from the US Patent and Trademark Office.
PBMD: 1.03 (-0.02)

US Patent Grants for IMP731 Antibody
Marketwired - Wed Jan 27, 5:00PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company"

announces the granting of patent number US 9,244,059 entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" by the United States Patent and Trademark Office.
PBMD: 1.03 (-0.02)

Prima BioMed to start Phase I melanoma study of IMP321 across Australia
M2 - Wed Jan 27, 3:16AM CST
Immuno-oncology company Prima BioMed (ASX

RR) (NASDAQ

BMD) announced on Tuesday that TACTI-mel, a Phase I clinical study in melanoma using its lead compound IMP321, will now commence in the Gallipoli Medical Research Foundation at the Greenslopes Private Hospital in Queensland, Austrlaia.
PBMD: 1.03 (-0.02)

Prima BioMed Initiates Phase I Melanoma Study in Australia
Marketwired - Tue Jan 26, 4:51PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce the initiation of the first clinical trial site for TACTI-mel, a Phase I clinical study in melanoma using its lead compound IMP321, to be conducted in Australia.
PBMD: 1.03 (-0.02)

Prima BioMed Initiates Phase IIb Study in Metastatic Breast Cancer
Marketwired - Tue Dec 22, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 1.03 (-0.02)

4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Fri Dec 11, 8:51AM CST
NEW YORK, NY / ACCESSWIRE / December 11, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
EYES: 4.03 (-0.68), PBMD: 1.03 (-0.02), CGEN: 6.43 (-0.19), ONTY: 1.21 (+0.02)

Prima BioMed Progresses Japanese Collaboration
Marketwired - Fri Dec 11, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) today announces important progress in its collaboration with NEC Corporation and Yamaguchi University in Japan. In this collaboration, first announced in May 2015, Prima's IMP321 Antigen Presenting Cell activator (APC) is being combined with a therapeutic vaccine for different carcinoma types that was developed at Yamaguchi University.
PBMD: 1.03 (-0.02)

Prima BioMed Unveils Phase I Combination Study of IMP321 + Checkpoint Inhibitor
Marketwired - Wed Nov 18, 6:00AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 1.03 (-0.02)

Prima BioMed announces AUD2.0m from equity placement with an Australian Institution
M2 - Mon Nov 02, 4:19AM CST
Immuno-oncology company Prima BioMed (ASX

RR) (NASDAQ

BMD) said on Friday that it has raised AUD2.0m in an equity placement with an Australian Institution.
PBMD: 1.03 (-0.02)

Prima BioMed Raises A$2.0 Million Through Placement to Leading Australian Institution
Marketwired - Fri Oct 30, 6:01AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, announces that it has raised A$2.0 million via an equity placement at A$0.05 per ordinary ASX listed share to a leading Australian institutional investor.
PBMD: 1.03 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lean Focus Expands: Bridging Global Expertise in APAC

A New Era for Lean Focus in the Asia Pacific The wave of business dynamics in APAC just got a little more intense. Lean Focus has thrown its hat in the ring, expanding into the Asia Pacific—a move that could shift how businesses operate in this bustling region. Forget the corporate hype for a moment and think about what this really means: local expertise, hands-on...

PMET Exec Shakeup as Shaakichiuwaanaan Nears Development

Turning Wheels at PMET: Leadership Shuffle in Motion There's a changing of the guard over at PMET Resources as they brace for the next big steps with their Shaakichiuwaanaan Project. Ken Brinsden, their long-time President and CEO, has decided it's time to pass the baton down the line, transitioning to Executive Chair next year. This move is all about keeping a steady...

Creative Solutions Joins FICO Marketplace, Boosts AI Edge

Creative Solutions and FICO Unite Well, we're diving into some strategic magic today. Creative Solutions International, not just your average marketing agency, has just hopped onto the FICO Marketplace platform. The word on the street is they're shaking things up with their Collections Marketing Platform. It's like giving your old financial letters a whole AI-driven paint...

Florida's Insurance Premiums: Why They Keep Skyrocketing

What’s Driving Up These Premiums? If you’ve ever felt like your wallet gets lighter every time you pay your insurance premium, welcome to the club. It seems like the cost of insurance in Florida is like a runaway train. But don't just blame the hurricanes. Yeah, they definitely play their part, but there’s a bigger picture lurking behind those price tags. Weather...

Boosting Employability: English Skills in Italy's Job Market

Tackling Language Barriers in Italy's Workforce If you're looking to make it big in Italy, you're facing a task that demands more than just regional expertise. The working world is no longer bound by borders, and for Italians eyeing international gigs, English fluency is a must-have. While not an absolute ticket to success, grasping English could be your career's booster...

Wison's Flex-to-X: Shaping Future of Green Energy

Cracking the Code: Wison's Flex-to-X Debut You'll never catch me tossing into new tech fads blindly, but Wison Engineering's launch of Flex-to-X during ADIPEC 2026 has truly piqued my interest. We're talking about a serious move for green fuels and chemicals, using their chops in modular execution as a springboard into something bigger. From Engineer-to-Order to...

Dutch Bros Launches 'Passenger Princess' Event with New Drink

Frothy Celebrations for Passenger Princesses There's a fresh hue tinkling across the drive-thru circuit this November, dipped in audacity and powered by social trend winds. Dutch Bros, that lively drive-thru kingpin, is capitalizing on a viral TikTok trend by rolling out the pink carpet for its third annual National Passenger Princess Day. And this ain't just a one-day...

Pharmacy Credentials Gain Importance in Delaware Law

Credentialing Takes Front Seat in Pharmacy World Well, hold onto your hats because the pharmacy profession is getting a major upgrade, particularly if you're an investor watching healthcare regulation. The American Association of Colleges of Pharmacy (AACP) has thrown its support behind professional credentialing for pharmacists, which is a big deal, trust me. Pharmacy...

Cognizant Boosts Claude AI with 25,000 Pro Workforce

Moving AI from Theory to Practice You know, AI isn't about just keeping up with the hype; it's about shoving those algorithms right where they can do the most good—right at the core of business operations. And that’s precisely what Cognizant's cooking up with their fresh-off-the-press Claude Frontier Capability Group. They’ve thrown more than 25,000 pros into the...

International Tower Hill's Q3 Results: Gold Updates

An Eye on International Tower Hill's Latest Moves You've got International Tower Hill Mines (TSX: ITH, NYSE American: THM) laying their cards on the table for the third quarter. This ain't just any routine check-in—it's a glimpse at their Livengood Gold Project, standing tall on the promise of gold beyond the horizon. A cool $106 million in cash? Not too shabby, folks....